{"id":24351,"date":"2019-02-12T12:00:00","date_gmt":"2019-02-12T12:00:00","guid":{"rendered":"https:\/\/www.euforea.org\/news\/conclusion-sur-les-defis-lies-a-ladoption-des-biomedicaments-chez-les-patients-atteints-de-crswnp-et-dasthme\/"},"modified":"2019-02-12T12:00:00","modified_gmt":"2019-02-12T12:00:00","slug":"conclusion-sur-les-defis-lies-a-ladoption-des-biomedicaments-chez-les-patients-atteints-de-crswnp-et-dasthme","status":"publish","type":"news","link":"https:\/\/www.euforea.org\/fr\/news\/conclusion-sur-les-defis-lies-a-ladoption-des-biomedicaments-chez-les-patients-atteints-de-crswnp-et-dasthme\/","title":{"rendered":"Conclusion sur les d\u00e9fis li\u00e9s \u00e0 l\u2019adoption des biom\u00e9dicaments chez les patients atteints de CRSwNP et d\u2019asthme"},"content":{"rendered":"<div class=\"paragraph paragraph--text-columns paragraph-id--1481 paragraph--type--text-columns paragraph--view-mode--default clearfix paragraph--text-columns--1col\">\n<div class=\"inner--wide\">\n<div class=\"text__text text text--paragraph\">\n<h2>Rhinology Future Debates Bruxelles 2018<\/h2>\n<p>Dans cette courte vid\u00e9o, le Pr dr Claus Bachert partage ses r\u00e9flexions sur la th\u00e9rapie et les anticorps monoclonaux.<\/p>\n<h3>Pan\u00e9listes<\/h3>\n<p>Catherine Lucet, Claus Bachert, Joaquim Mullol, Peter Hellings, Charles Pilette, Renaud Louis, Philippe Rombaux, repr\u00e9sentants des patients.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<div class=\"paragraph paragraph--text-columns paragraph-id--1482 paragraph--type--text-columns paragraph--view-mode--default clearfix paragraph--text-columns--1col\">\n<div class=\"inner--wide\">\n<div class=\"text__text text text--paragraph\">\n<div class=\"video-container\"><center><iframe title=\"Lecteur vid\u00e9o YouTube\" src=\"https:\/\/www.youtube.com\/embed\/ItSpdFhs_cA?rel=0\" width=\"560\" height=\"315\" frameborder=\"0\" allowfullscreen=\"allowfullscreen\"><\/iframe><\/center><\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Rhinology Future Debates Bruxelles 2018 Dans cette courte vid\u00e9o, le Pr dr Claus Bachert partage ses r\u00e9flexions sur la th\u00e9rapie et les anticorps monoclonaux. Pan\u00e9listes Catherine Lucet, Claus Bachert, Joaquim Mullol, Peter Hellings, Charles Pilette, Renaud Louis, Philippe Rombaux, repr\u00e9sentants des patients.<\/p>\n","protected":false},"author":1,"featured_media":24361,"comment_status":"open","ping_status":"closed","template":"","meta":{"footnotes":""},"categories":[189],"tags":[174,175,190,191,192,194,196,170,172],"class_list":["post-24351","news","type-news","status-publish","has-post-thumbnail","hentry","category-rhinology-future-debates","tag-crswnp","tag-biotherapies","tag-rhinologie","tag-debats","tag-rhinology-future-debates","tag-rhinosinusite-chronique-rsc","tag-patients","tag-professionnels-de-sante","tag-asthme"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v28.3 (Yoast SEO v28.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Conclusion sur les d\u00e9fis li\u00e9s \u00e0 l\u2019adoption des biom\u00e9dicaments chez les patients atteints de CRSwNP et d\u2019asthme - EUFOREA<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.euforea.org\/fr\/news\/conclusion-sur-les-defis-lies-a-ladoption-des-biomedicaments-chez-les-patients-atteints-de-crswnp-et-dasthme\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Conclusion sur les d\u00e9fis li\u00e9s \u00e0 l\u2019adoption des biom\u00e9dicaments chez les patients atteints de CRSwNP et d\u2019asthme\" \/>\n<meta property=\"og:description\" content=\"Rhinology Future Debates Bruxelles 2018 Dans cette courte vid\u00e9o, le Pr dr Claus Bachert partage ses r\u00e9flexions sur la th\u00e9rapie et les anticorps monoclonaux. Pan\u00e9listes Catherine Lucet, Claus Bachert, Joaquim Mullol, Peter Hellings, Charles Pilette, Renaud Louis, Philippe Rombaux, repr\u00e9sentants des patients.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.euforea.org\/fr\/news\/conclusion-sur-les-defis-lies-a-ladoption-des-biomedicaments-chez-les-patients-atteints-de-crswnp-et-dasthme\/\" \/>\n<meta property=\"og:site_name\" content=\"EUFOREA\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/euforea\/\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@euforea\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/fr\\\/news\\\/conclusion-sur-les-defis-lies-a-ladoption-des-biomedicaments-chez-les-patients-atteints-de-crswnp-et-dasthme\\\/\",\"url\":\"https:\\\/\\\/www.euforea.org\\\/fr\\\/news\\\/conclusion-sur-les-defis-lies-a-ladoption-des-biomedicaments-chez-les-patients-atteints-de-crswnp-et-dasthme\\\/\",\"name\":\"Conclusion sur les d\u00e9fis li\u00e9s \u00e0 l\u2019adoption des biom\u00e9dicaments chez les patients atteints de CRSwNP et d\u2019asthme - EUFOREA\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/fr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/fr\\\/news\\\/conclusion-sur-les-defis-lies-a-ladoption-des-biomedicaments-chez-les-patients-atteints-de-crswnp-et-dasthme\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/fr\\\/news\\\/conclusion-sur-les-defis-lies-a-ladoption-des-biomedicaments-chez-les-patients-atteints-de-crswnp-et-dasthme\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/s3.nl-ams.scw.cloud\\\/euforea-wp-production\\\/uploads\\\/Rhinology20Future20Debates202018_22.png\",\"datePublished\":\"2019-02-12T12:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/fr\\\/news\\\/conclusion-sur-les-defis-lies-a-ladoption-des-biomedicaments-chez-les-patients-atteints-de-crswnp-et-dasthme\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.euforea.org\\\/fr\\\/news\\\/conclusion-sur-les-defis-lies-a-ladoption-des-biomedicaments-chez-les-patients-atteints-de-crswnp-et-dasthme\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/fr\\\/news\\\/conclusion-sur-les-defis-lies-a-ladoption-des-biomedicaments-chez-les-patients-atteints-de-crswnp-et-dasthme\\\/#primaryimage\",\"url\":\"https:\\\/\\\/s3.nl-ams.scw.cloud\\\/euforea-wp-production\\\/uploads\\\/Rhinology20Future20Debates202018_22.png\",\"contentUrl\":\"https:\\\/\\\/s3.nl-ams.scw.cloud\\\/euforea-wp-production\\\/uploads\\\/Rhinology20Future20Debates202018_22.png\",\"width\":1280,\"height\":720},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/fr\\\/news\\\/conclusion-sur-les-defis-lies-a-ladoption-des-biomedicaments-chez-les-patients-atteints-de-crswnp-et-dasthme\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.euforea.org\\\/fr\\\/choisissez-votre-parcours\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"News\",\"item\":\"https:\\\/\\\/www.euforea.org\\\/fr\\\/news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Conclusion sur les d\u00e9fis li\u00e9s \u00e0 l\u2019adoption des biom\u00e9dicaments chez les patients atteints de CRSwNP et d\u2019asthme\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.euforea.org\\\/fr\\\/\",\"name\":\"EUFOREA\",\"description\":\"Inspiring the Future of Respiratory Care\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.euforea.org\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/fr\\\/#organization\",\"name\":\"EUFOREA\",\"url\":\"https:\\\/\\\/www.euforea.org\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/s3.nl-ams.scw.cloud\\\/euforea-wp-production\\\/uploads\\\/euforea.png\",\"contentUrl\":\"https:\\\/\\\/s3.nl-ams.scw.cloud\\\/euforea-wp-production\\\/uploads\\\/euforea.png\",\"width\":500,\"height\":500,\"caption\":\"EUFOREA\"},\"image\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/euforea\\\/\",\"https:\\\/\\\/x.com\\\/euforea\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/euforea\",\"https:\\\/\\\/www.youtube.com\\\/c\\\/EUFOREA\",\"https:\\\/\\\/www.instagram.com\\\/euforeaofficial\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Conclusion sur les d\u00e9fis li\u00e9s \u00e0 l\u2019adoption des biom\u00e9dicaments chez les patients atteints de CRSwNP et d\u2019asthme - EUFOREA","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.euforea.org\/fr\/news\/conclusion-sur-les-defis-lies-a-ladoption-des-biomedicaments-chez-les-patients-atteints-de-crswnp-et-dasthme\/","og_locale":"fr_FR","og_type":"article","og_title":"Conclusion sur les d\u00e9fis li\u00e9s \u00e0 l\u2019adoption des biom\u00e9dicaments chez les patients atteints de CRSwNP et d\u2019asthme","og_description":"Rhinology Future Debates Bruxelles 2018 Dans cette courte vid\u00e9o, le Pr dr Claus Bachert partage ses r\u00e9flexions sur la th\u00e9rapie et les anticorps monoclonaux. Pan\u00e9listes Catherine Lucet, Claus Bachert, Joaquim Mullol, Peter Hellings, Charles Pilette, Renaud Louis, Philippe Rombaux, repr\u00e9sentants des patients.","og_url":"https:\/\/www.euforea.org\/fr\/news\/conclusion-sur-les-defis-lies-a-ladoption-des-biomedicaments-chez-les-patients-atteints-de-crswnp-et-dasthme\/","og_site_name":"EUFOREA","article_publisher":"https:\/\/www.facebook.com\/euforea\/","twitter_card":"summary_large_image","twitter_site":"@euforea","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.euforea.org\/fr\/news\/conclusion-sur-les-defis-lies-a-ladoption-des-biomedicaments-chez-les-patients-atteints-de-crswnp-et-dasthme\/","url":"https:\/\/www.euforea.org\/fr\/news\/conclusion-sur-les-defis-lies-a-ladoption-des-biomedicaments-chez-les-patients-atteints-de-crswnp-et-dasthme\/","name":"Conclusion sur les d\u00e9fis li\u00e9s \u00e0 l\u2019adoption des biom\u00e9dicaments chez les patients atteints de CRSwNP et d\u2019asthme - EUFOREA","isPartOf":{"@id":"https:\/\/www.euforea.org\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.euforea.org\/fr\/news\/conclusion-sur-les-defis-lies-a-ladoption-des-biomedicaments-chez-les-patients-atteints-de-crswnp-et-dasthme\/#primaryimage"},"image":{"@id":"https:\/\/www.euforea.org\/fr\/news\/conclusion-sur-les-defis-lies-a-ladoption-des-biomedicaments-chez-les-patients-atteints-de-crswnp-et-dasthme\/#primaryimage"},"thumbnailUrl":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/Rhinology20Future20Debates202018_22.png","datePublished":"2019-02-12T12:00:00+00:00","breadcrumb":{"@id":"https:\/\/www.euforea.org\/fr\/news\/conclusion-sur-les-defis-lies-a-ladoption-des-biomedicaments-chez-les-patients-atteints-de-crswnp-et-dasthme\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.euforea.org\/fr\/news\/conclusion-sur-les-defis-lies-a-ladoption-des-biomedicaments-chez-les-patients-atteints-de-crswnp-et-dasthme\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.euforea.org\/fr\/news\/conclusion-sur-les-defis-lies-a-ladoption-des-biomedicaments-chez-les-patients-atteints-de-crswnp-et-dasthme\/#primaryimage","url":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/Rhinology20Future20Debates202018_22.png","contentUrl":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/Rhinology20Future20Debates202018_22.png","width":1280,"height":720},{"@type":"BreadcrumbList","@id":"https:\/\/www.euforea.org\/fr\/news\/conclusion-sur-les-defis-lies-a-ladoption-des-biomedicaments-chez-les-patients-atteints-de-crswnp-et-dasthme\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.euforea.org\/fr\/choisissez-votre-parcours\/"},{"@type":"ListItem","position":2,"name":"News","item":"https:\/\/www.euforea.org\/fr\/news\/"},{"@type":"ListItem","position":3,"name":"Conclusion sur les d\u00e9fis li\u00e9s \u00e0 l\u2019adoption des biom\u00e9dicaments chez les patients atteints de CRSwNP et d\u2019asthme"}]},{"@type":"WebSite","@id":"https:\/\/www.euforea.org\/fr\/#website","url":"https:\/\/www.euforea.org\/fr\/","name":"EUFOREA","description":"Inspiring the Future of Respiratory Care","publisher":{"@id":"https:\/\/www.euforea.org\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.euforea.org\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.euforea.org\/fr\/#organization","name":"EUFOREA","url":"https:\/\/www.euforea.org\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.euforea.org\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/euforea.png","contentUrl":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/euforea.png","width":500,"height":500,"caption":"EUFOREA"},"image":{"@id":"https:\/\/www.euforea.org\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/euforea\/","https:\/\/x.com\/euforea","https:\/\/www.linkedin.com\/company\/euforea","https:\/\/www.youtube.com\/c\/EUFOREA","https:\/\/www.instagram.com\/euforeaofficial\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.euforea.org\/fr\/wp-json\/wp\/v2\/news\/24351","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.euforea.org\/fr\/wp-json\/wp\/v2\/news"}],"about":[{"href":"https:\/\/www.euforea.org\/fr\/wp-json\/wp\/v2\/types\/news"}],"author":[{"embeddable":true,"href":"https:\/\/www.euforea.org\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euforea.org\/fr\/wp-json\/wp\/v2\/comments?post=24351"}],"version-history":[{"count":0,"href":"https:\/\/www.euforea.org\/fr\/wp-json\/wp\/v2\/news\/24351\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.euforea.org\/fr\/wp-json\/wp\/v2\/media\/24361"}],"wp:attachment":[{"href":"https:\/\/www.euforea.org\/fr\/wp-json\/wp\/v2\/media?parent=24351"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euforea.org\/fr\/wp-json\/wp\/v2\/categories?post=24351"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euforea.org\/fr\/wp-json\/wp\/v2\/tags?post=24351"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}